openPR Logo
Press release

Dyslipidemia Therapeutics Market Research Report 2017-2025: by Product Type, Distribution Channel, by Geography and Company Profile

Dyslipidemia Therapeutics Market

Dyslipidemia Therapeutics Market

Dyslipidemia is one of the metabolic disorder, which is described by unbalanced level and thickness of lipoproteins and triglycerides. The disorder also includes protein deficiency and over production. These disorders can be caused by increase in the serum total cholesterol, triglyceride concentrations, and low-density lipoprotein (LDL) cholesterol, and a decrease in the high-density lipoprotein (HDL) cholesterol concentration. These condition are mainly associated with cardiovascular or coronary heart disease. The other cause of this disease includes hypothyroidism and genetic predisposition. Rise in triglyceride concentration might also lead to the diabetes mellitus, obesity and hypothyroidism. The treatment of dyslipidemia includes lifestyle modification, exercise & weight reduction, nutrition supplement and drug therapy.

Read Report @ https://www.persistencemarketresearch.com/market-research/dyslipidemia-therapeutics-market.asp

The global market for dyslipidemia therapeutics is expected to be driven by the increasing incidence of dyslipidemia and cardiovascular disease, growing obese population prone to cardiovascular disease due to sedentary lifestyle. Few of the drivers of the market are the growing R&D activities by leading players for the development of novel drugs, increasing diagnosis rate among patient population and increasing awareness in developing economies. Moreover, the increasing research activities on stain and non-stain based therapeutics for cardiovascular and associated disease, preclinical research activities and growing collaboration between research institutes, biotechnology and biopharmaceuticals companies are expected to drive the market during the forecast period. However, the high cost of drug development and pre-clinical activities, high cost of therapeutics to the end users, stringent regulation and lengthy approval process might hamper the market growth to some extent.

Request Sample Report @ https://www.persistencemarketresearch.com/samples/14401

Global dyslipidemia therapeutics market is experiencing significant growth owing to increased need for high cholesterol management, prevention of cardiovascular disease (CVD), and sedentary lifestyle leading to growing obese population across the globe. Based on product type, the market is segmented into stain and non-stain drugs. Stain drugs are majorly used as primary treatment option for dyslipidemia. Stain drugs are classified as high-intensity, moderate-intensity and low-intensity.

Based on distribution channel, the global dyslipidemia therapeutics market has been segmented into hospital pharmacies, drug stores, retail pharmacies, and online pharmacies. Hospital pharmacies distribution channel segment is expected to grow at the higher rate over the forecast period due to increasing purchase of prescription drugs and growing diagnosis rate of dyslipidemia across the globe. Moreover recent development of for the development of cholesterol lowering drugs, ongoing R&D activities in this therapeutics area and presence of research driven players in the market may help grow this market significantly.

Geographically dyslipidemia therapeutics market is classified into regions viz. North America, Latin America, Europe, Asia-Pacific, Middle East and Africa. North America and Europe will remain key markets for dyslipidemia therapeutics market due to high diagnosis and incidence rate of dyslipidemia due to sedentary lifestyle and obese population prone to cardio vascular disease. Moreover, presence of sophisticated healthcare infrastructure, awareness about the disease among population and high purchasing power are few of the factors responsible for the market growth. Asia Pacific is anticipated to register positive growth owing to rising government’s initiatives in healthcare sector, improved healthcare infrastructure and increased population in the region.

Buy now @ https://www.persistencemarketresearch.com/checkout/14401

Some of the key players in the dyslipidemia therapeutics market are Novartis AG, Merck & Co., Inc, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Eli Lilly, AstraZeneca plc, Amgen Inc., to name a few. Companies are now focusing on the development of novel therapeutics. For example, PCSK9 Inhibitors is new therapy used for cholesterol management. In July 2015, FDA approved Alirocumab (Praluent®), a PCSK9 Inhibitor, manufactured by Sanofi and evolocumab (Repatha™), manufactured by Amgen Inc. in August 2015.

About Us

Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact Us

Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dyslipidemia Therapeutics Market Research Report 2017-2025: by Product Type, Distribution Channel, by Geography and Company Profile here

News-ID: 851169 • Views:

More Releases from Persistance Market Research

Evolving Trends in the Insulin Pens Market: A Comprehensive Report
Evolving Trends in the Insulin Pens Market: A Comprehensive Report
Market Overview: The Insulin Pens Market has witnessed remarkable growth and innovation over the years. Insulin pens are medical devices used by individuals with diabetes to administer insulin easily and accurately. These devices have become an integral part of diabetes management, offering numerous advantages over traditional insulin delivery methods, such as syringes and vials. In 2022, the global market for insulin pens brought in US$ 16.2 billion in revenue and is predicted
Smart Machines Market to register growth at a CAGR of 20.1% throughout 2023-2033
The market for smart machines was valued at US$ 73,456.2 Mn in 2022, and it is expected to grow to US$ 5,44,986.6 Mn by the end of 2033. In 2023, the market for smart machines is expected to be worth US$ 87,045.6 Mn. From 2023 to 2033, the market for Smart Machines is expected to grow at a CAGR of 20.1%. The market for artificially intelligent machines and systems that can
Unified Cloud Communication and Collaboration Market will register a 11.1% CAGR by 2032
Unified Cloud Communication and Collaboration Market will register a 11.1% CAGR …
The global cloud collaboration market was valued at US$ 48 billion in 2022, and it is expected to grow at an 11.1% CAGR, likely reaching US$ 137.3 billion by the end of the forecast period, which runs from 2022 to 2032. The expansion of organizations' cross-border projects, increased productivity, and the rise of the bring your own device (BYOD) trend are some of the major factors expected to drive the
Optical Transceivers Market is Set to Grow At A CAGR Of 14.6 % By 2032
Optical Transceivers Market is Set to Grow At A CAGR Of 14.6 % By 2032
Persistence Market Research's new report "Optical Transceivers Market" examines the competitive landscape and the market's growth prospects in the coming years. The report of the Optical Transceivers market for the analysis period of 2023 - 2033 includes an in-depth study of some new and prominent industry trends, engagement analysis, and detailed regional analysis. Need More Insights on Competitor Analysis of the Smart Home Cloud Platform Market, Request for Sample https://www.persistencemarketresearch.com/samples/4798 Through

All 5 Releases


More Releases for Dyslipidemia

Dyslipidemia drugs Market - Growth Dynamics 2025
Global Dyslipidemia Drugs Market: Snapshot Dyslipidemia is a cardiovascular condition comprising of changes in the amount of lipids in the blood. Dyslipidemia can show as either absence of or abundance of lipids in blood; hyperlipidemia, the state of having overabundance lipids in the blood, is probably going to hold the major share in the global dyslipidemia drugs market in the within the forecast period. Various issues related with dietary habits and
Dyslipidemia drugs Market Electrification Rate of 2025
Global Dyslipidemia Drugs Market: Snapshot Dyslipidemia is a cardiovascular condition comprising of changes in the amount of lipids in the blood. Dyslipidemia can show as either absence of or abundance of lipids in blood; hyperlipidemia, the state of having overabundance lipids in the blood, is probably going to hold the major share in the global dyslipidemia drugs market in the within the forecast period. Various issues related with dietary habits and
Dyslipidemia - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Dyslipidemia - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H2 2017, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape. Dyslipidemia is defined as elevation of the total cholesterol, the ""bad"" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a
Dyslipidemia Drugs Market | Global Industry Analysis 2023
The top five players in the Global Dyslipidemia Drugs Market are AstraZeneca plc., Merck & Co., Inc., Pfizer, Inc., Daiichi Sankyo Company, Limited, and Abbott Laboratories. The cumulative share of these players in the global market was valued at 74.4% in 2014. The exclusivity in the rights of blockbuster drugs has been the primary growth driver for these companies. Analysts predict that intensive research and development activities by these players
Dyslipidemia - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Dyslipidemia - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2017, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape. Dyslipidemia is defined as elevation of the total cholesterol, the ""bad"" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a
Emerging Opportunities in Dyslipidemia Drugs Market
The top five players in the global dyslipidemia drugs market are AstraZeneca plc., Merck & Co., Inc., Pfizer, Inc., Daiichi Sankyo Company, Limited, and Abbott Laboratories. The cumulative share of these players in the global market was valued at 74.4% in 2014. The exclusivity in the rights of blockbuster drugs has been the primary growth driver for these companies. Analysts predict that intensive research and development activities by these players